Sector to Grow 7.5% Annually through 2028

Dublin, January 13, 2023 — (GLOBE NEWSWIRE). “North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028” A report has been added ResearchAndMarkets.com’s offering.

Market growth for North America Cell-based Assays Market is expected to be 7.5% CAGR over the forecast period (2022-2028).

These assays include cell viability and cell proliferation assays as well as GPCR assays. These high-throughput assays accelerate drug discovery by finding the most promising candidate in the biological context which matters most.

The drug development process has evolved from a limited target-based screening of basic cells that was not biologically relevant to multicellular cell-based biochemical or functional assays for disease-relevant platforms to a more comprehensive, targeted-based screening.

Recent years have seen the development of cell-based assays to help researchers understand the complex interactions between these pathways and networks. The best assays can be constructed to mimic the disease state if patients have access to multiple cell types and are able use both current and innovative technologies.

This will increase the performance of translational research. Cellular assays can be used for both biomedical research or drug discovery screening applications. They are also known as cell based assays. These assays can efficiently assess biological activity and cytotoxicity as well as biochemical processes and off-target interactions.

America’s society is affected by cancer. Statistics on cancer reflect the effects of large populations and give a temporal view of the social burden of this disease. The National Cancer Institute estimates that in the United States, there were an estimated 1,806,590 new cases of cancer and that 606,520 people died from the disease. The most common types are breast cancer, colon, rectum, lung, bronchus and prostate cancers. Also, non-Hodgkin lymphoma (non-Hodgkin), endometrial, thyroid, pancreatic and liver cancers.

In 2021, the North America Cell Based Assays Market By Country was dominated by the US market. This resulted in a market worth $7.2 billion by 2028. Canada is seeing a CAGR in the range of 10%-2028. A CAGR of 9% would be seen in the Mexico market between 2022-2028.

Scope of the Study
By Application

• Drug Discovery

• Basic Research

• Other

End-user

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Research Organizations (CROs).

By Products & Services

• Assay Kits

• Reagents

• Microplates

• Probes & Labels

• Instruments & Software

• Cell Lines

By Country

• US

• Canada

• Mexico

• Rest of North America

We cover the following key topics:

Chapter 1. Market Scope & Methodology

Chapter 2. Chapter 2. Market Overview

Chapter 3. Chapter 3.

Chapter 4. North America Cell-Based Assays Market by Application

Chapter 5. Chapter 5.

Chapter 6. North America Cell-based Assays Market by Products & Services

Chapter 7. Chapter 7.

Chapter 8. Chapter 8. Company Profiles

Companies Mentioned

• Becton, Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Corning Incorporated

• Charles River Laboratories International, Inc.

• Danaher Corporation

• F. Hoffmann-La Roche Ltd.

• Lonza Group AG

• Merck Group

• Promega Corporation

• Thermo Fisher Scientific, Inc.

This report has more information, visit https://www.researchandmarkets.com/r/qifq12

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide the most up-to-date data on global and regional markets as well as key industries and top companies.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900